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http://www.ovarianresearch.com/content/7/1/61RESEARCH Open AccessThe expression of the Sprouty 1 protein inversely
correlates with growth, proliferation, migration
and invasion of ovarian cancer cells
Samar Masoumi-Moghaddam1, Afshin Amini1, Anahid Ehteda1, Ai-Qun Wei2 and David Lawson Morris1*Abstract
Background: Our recent study on a panel of human ovarian cancer cells revealed that SKOV-3 cells barely express
the Sprouty isoform 1 (Spry1) while 1A9 cells maintain it at a level similar to normal ovarian cells. Here we investigated
the functional outcomes of induced alterations in the expression of Spry1 in the two cell lines in vitro.
Methods: Using the Spry1 specific plasmid and siRNA, the expression of Spry1 was induced and conversely
silenced in SKOV-3 and 1A9 cells, respectively. The functional outcome was investigated by means of proliferation,
MTT, scratch-wound, migration and invasion assays and selection of the stable clones. Mechanism of the effect
was explored by Western blot.
Results: In the Spry1-transfected SKOV-3 cells, a significant reduction in growth and proliferation was evident.
Stable clones of the Spry1-transfected SKOV-3 were almost undetectable after day 14. The number of migrated
and invaded cells and the percentage of the scratch closure were significantly lower in the Spry1-transfected
group. Spry1 silencing in 1A9 cells, on the other hand, led to a significant increase in cell growth and proliferation.
The number of migrated and invaded cells and the percentage of the scratch closure significantly increased in
Spry1-silenced 1A9 group. Mechanistically, overexpression of Bax, activation of caspases 3, 7, 8 and 9, cleavage of
PARP and attenuation of Bcl-2 and Bcl-xl were observed along with reduced activation of Erk and Akt and
increased amount and activity of PTEN in the Spry1-transfected SKOV-3 cells.
Conclusions: Here, we report the inverse correlation between the expression of Spry1 and growth, proliferation,
invasion and migration of ovarian cancer cells.
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The Sprouty protein family is a downstream modulator
of the receptor tyrosine kinase (RTK) signaling and thus
a major contributor to the regulation of the eukaryotic
cells biology. Up to now, four mammalian isoforms of
the protein, designated Spry1-4, have been identified.
Spry1, the first isoform to be discovered, was initially in-
troduced as a potent feedback inhibitor of the FGF re-
ceptor signaling during the tracheal development of the
Drosophila embryos [1]. Owing to their regulatory func-
tion, deregulation of Sprouty proteins and its contribution* Correspondence: david.morris@unsw.edu.au
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article, unless otherwise stated.to pathophysiology of cancer have been studied in differ-
ent malignancies [2]. Carcinomas of the breast [3] and
prostate [4], for example, have reportedly been associated
with Spry1 downregulation. Preclinically, anti-proliferative
and tumor suppressing roles have been described for
Spry1 in prostate [4], liver [5] and medullary thyroid can-
cer cells [6]. Spry1 has also been implicated as a marker of
good prognosis in patients with renal cell carcinoma [7].
Our prior work showed that Spry1 is downregulated in
the majority of the ovarian cancer cell lines studied [8].
Since there clearly is a need for further investigation ex-
ploring the role of Spry1 in the context of ovarian cancer,
we examined in the present study the correlation between
the expression of Spry1 and the biological behavior of
ovarian cancer cells. Using two cell lines with distinctBioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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ations in the protein expression impact functional proper-
ties of ovarian cancer cells.
Methods
Cell culture
Human ovarian cancer cell lines SKOV-3 and 1A9, a vari-
ant derived from A2780 [9], were obtained from the
American Type Culture Collection (ATCC) (Manassas,
VA, USA) and were maintained in a humidified 5% CO2
incubator at 37°C in RPMI-1640 (Invitrogen, CA, USA)
supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin mixture (Invitrogen, CA, USA).
Transfection and silencing
Electroporation-based transfection and silencing were
carried out using 4D-Neucleofector System and SF Cell
Line 4D-Neucleofector Kit (Lonza Group, Basel,
Switzerland) according to the manufacturer’s protocol
after initial optimization for the cell lines. The two nega-
tive controls designed for the transfection experiments
included “-vector” (plasmid-free) and “+vector” (vector
only) transfection groups. For transient transfection,
SKOV-3 cells were washed with PBS, detached with
trypsin and suspended in the supplemented Nucleofec-
tor Solution SF (2 × 106/100 μl). After adding the
pcDNA3.1/Spry1 construct and pcDNA3.1 empty vector
(Invitrogen, Life Technologies, CA, USA) to the Spry1-
transfection and + vector samples, respectively, all sam-
ples were transferred into the 4D-Neucleofector device
and the reaction was run with the optimized program
(pulse code: EH-100). Samples were then transferred to
the culture vessels and cultured for further analysis. For
the stable transfection experiment, exposure to the se-
lection condition (culture media containing G418-
Geneticin (Gibco, Life Technologies, CA, USA) at a final
concentration of 300 μg/ml) for selection of the stably-
transfected clones was started two days post-transfection.
On day 14 post-selection, Geneticin-resistant clones
were fixed with 100% methanol and stained with crystal
violet. Transient silencing of Spry1 in 1A9 cells was per-
formed using Spry1 Pre-design Chimera RNAi (Abnova,
Taiwan). Reaction was similarly carried out using 4D-
Neucleofector System set up for the cell line (pulse
code: EN-138). Efficiency of the electroporation was
evaluated by visualization of the green fluorescent protein
(GFP) encoded by the co-transfected control plasmid
(pmaxGFP Vector (Lonza Group, Basel, Switzerland))
showing transfection efficiency of >80%, as well as by
western blot analysis of the Spry1 expression in the con-
trol transfected or silenced cells. The specificity of the
constructs and plasmids were confirmed by western blot
as the expression of other members of the Sprouty family
was found unaffected.Western blotting
At the endpoints, cultured cells were homogenized in a
protein lysis buffer (RIPA buffer) containing 10% prote-
ase inhibitor (Sigma-Aldrich, Missouri, USA) and the
protein concentrations were quantified by BioRad pro-
tein assay (Bio-Rad, CA, USA). Then, the same amounts
of the proteins were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, transferred to
PVDF membranes (Millipore Corporation, MA, USA).
The following primary antibodies were then applied to
the membranes according to the manufacturers’ proto-
cols: rabbit polyclonal anti-caspase 3, anti-Bcl2 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-caspase
8 (R&D Systems, Minneapolis, MN, USA), anti-caspase
9, anti-PARP, anti-Akt, anti-Phospho-PTEN, rabbit
monoclonal anti-caspase 7, anti-Bcl-xl, anti-Bax, anti-
phospho-Akt, anti-ERK, anti-phospho-ERK, anti-PTEN
(Cell Signaling Technology Inc, Danvers, MA, USA),
and mouse monoclonal anti-Spry1 (Abnova, Taiwan).
The membranes were washed and treated with appropri-
ate horseradish peroxidase-conjugated secondary anti-
bodies (Cell Signaling Technology Inc, Danvers, MA,
USA). Similar process was carried out for the GAPDH
protein, as a loading control, using 1:20000-diluted anti-
GAPDH mouse monoclonal antibody (Sigma-Aldrich,
Missouri, USA). The antigen-antibody reaction was digi-
tized with ImageQuant LAS 4000 Biomolecular imager
and ImageQuant software (GE Healthcare, UK).MTT assay
Appropriate number of the Spry1-transfected SKOV-3
cells and Spry1-silenced 1A9 cells along with equal
number of their respective controls were cultured in 96-
well plates at 37°C in 5% CO2 incubator for 24, 48 and
72 hours. At the endpoints, cells were incubated with
Thiazolyl Blue Tetrazolium Bromide (Sigma-Aldrich,
Missouri, USA) at a concentration of 0.5 mg/ml for fur-
ther 4 hours. Resulting formazan crystals were dissolved
with 100 μl of dimethyl sulfoxide (DMSO) and absorb-
ance was read using PowerWaveX microplate reader
(Bio-Tek Instruments Inc, VT, USA) at the working
wavelength of 562 nm.Trypan blue assay
Appropriate number of the Spry1-transfected SKOV-3
cells and Spry1-silenced 1A9 cells along with equal
number of their respective controls were cultured in 6-
well plates. At 24 h, 48 h and 72 h after plating, cells
were trypsinized and resuspended in medium. Cell sus-
pensions were then diluted 1:10 in trypan blue and the
actual number of the cells was calculated using a
hemocytometer.
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Control, Spry1-transfected and Spry1-silenced cells were
grown to confluence and the cell monolayers were
scraped with the tip of a pipette to create a uniform
scratch. The culture media were then replaced with fresh
media supplemented with 2% FBS and the reference
points for imaging were marked. Using Leica DM IRB
microscope equipped with Leica DC200 camera and
IM50 software (Leica Microsystems, Germany), plates
were viewed with a 5X objective and sequential imaging
was performed at the given time points. Images were
then analyzed with ImageJ software (Research Services
Branch, National Institutes of Health, USA) and the re-
sults were quantified by measuring the percentage of the
scratch closure.
Cell migration and invasion assays
24-well Transwell system with polycarbonate mem-
branes of 8 mm pore size was used for cell migration
and invasion assays. Briefly, 24 hours post transfection,
appropriate amount of cell suspensions (5 × 104 SKOV-3
cells or 1 × 105 1A9 cells in 500 μl of 0.1% BSA/RPMI
per well) was transferred to the upper compartments of
the Boyden chambers either coated with matrigel (BD
Biosciences, NJ, USA) for invasion assay or without
matrigel coating (Corning Life Sciences, MA, USA) for
migration assay. Lower compartments were filled with
750 μl of the same medium supplemented with 10%
FBS. Cells were then allowed to migrate and invade at
37°C. At the given time points, content of the upper
compartment was discarded and upper surface of the
membrane was wiped with a cotton swab. Cells on the
lower surface of the membrane were fixed in 100%
methanol, stained with Giemsa and counted under the
light microscope in at least eight different fields across
the membrane.
Statistical analysis
All data presented are representative of three independ-
ent experiments performed in triplicate. Statistical ana-
lysis was conducted using GraphPad InStat (GraphPad
Prism 6, San Diego, California, USA). Student’s t-test
was applied for unpaired samples and P values < 0.05
were considered significant. Since no significant difference
was found between the data from + vector and -vector
controls in the experiments with transiently-transfected
SKOV-3, +vector was considered as their negative control
for the statistical analysis.
Results
Induced expression of Spry1 is deleterious for viability of
the ovarian cancer cell line SKOV-3
We previously demonstrated that the human ovarian
cancer cell line SKOV-3 barely expresses Spry1 [8]. Toassess the effect of the Spry1 expression on ovarian can-
cer biology, we intended to examine viability of SKOV-3
cells after transfection with the plasmid encoding the
full-length sequence of Spry1 (Figure 1). Initially, the ex-
pression of the Spry1 protein was detected by Western
blot at 8, 24, 48 and 72 hours, post-transfection (Figure 1A).
Next, the impact of sustained as well as transient expres-
sion of the protein on the cell viability was evaluated. In
our stable transfection experiment under Geneticin
selection for 14 days, no Spry1-transfected clones sur-
vived whereas numerous colonies of the + vector SKOV-
3 formed (Figure 1B). Using the trypan blue (Figure 1C)
and MTT (Figure 1D) assays, we also found that the ex-
pression of Spry1 resulted in a significant decrease in
the growth and proliferation of the transfected cells at
72 hours post transfection (p-values of 0.0003 and
0.0042 for trypan blue and MTT assay, respectively).
Taken together, we observed that induced expression of
the Spry1 adversely impacts the SKOV-3 cell viability,
in vitro.
Spry1 transfection of SKOV-3 cells diminishes migration
and invasion
To investigate the influence of the Spry1 expression on
other mitogen-dependent processes, three different as-
says were employed in the next step to compare the mo-
tility and invasion of the Spry1-transfected cells with
those of the negative control group (Figure 2). In the
scratch assay, the percent closure of the wounded area
in the Spry1 transfection group showed a significant
decline measured at hours 20 (p-value: 0.0232) and 24
(p-value: 0.0046) after scratch (Figure 2A). Results from
the migration assay (Figure 2B) indicated that the num-
ber of the Spry1-transfected cells migrated was signifi-
cantly lower than their control counterparts, 6 (p-value:
0.0090) and 12 hours (p-value: 0.0002) after plating. The
invasion assay (Figure 2C) similarly showed reduced num-
ber of the invaded cells in the Spry1 transfection group ex-
amined at hours 6 (p-value: 0.0159) and 12 (p-value:
0.0005). In sum, induced expression of Spry1 was associ-
ated with attenuation of the SKOV-3 cell motility and
invasion, in vitro.
Spry1 knockdown enhances growth and proliferation of
the 1A9 human ovarian cancer cells
As we reported previously [8], the human ovarian cancer
cell line 1A9 expresses the Spry1 protein. To evaluate
how the inhibited expression of the protein could affect
the ovarian cancer cell biology, Spry1 was initially si-
lenced in 1A9 cells using the specific siRNA (Figure 3),
with the protein expression being examined at 24, 48
and 72 hours post transfection (Figure 3A). Both the
Spry1-expressing (control) and Spry1-silenced cells were
then assayed for their ability to grow and proliferate. In
Figure 1 Effect of the induced expression of Spry1 on cell viability in SKOV-3 human ovarian cancer cells as compared to the negative
controls. The two control groups include the SKOV-3 cells transfected with pcDNA3.1 plasmid (+vector, Genticin resistant) and the SKOV-3 cells
with no plasmid transfection (−vector, Genticin sensitive). A. Western blot analysis of the protein expression in the Spry1-transfected cells as
compared to the controls. Results show expression of Spry1 examined at 8 (8 h-trans), 24 (24 h-trans), 48 (48 h-trans) and 72 hours (72 h-trans)
post-transfection. The Spry1-expressing cell line 1A9 was used as a positive control for the protein expression. GAPDH blot is shown as the
loading control of the experiment. B. Crystal violet staining of the Spry1-transfected, +vector and -vector SKOV-3 cells after 2 weeks under
Geneticin selection. As seen, no colony was formed by the Spry1-transfected and -vector cells. C. Trypan blue assay and; D. MTT assay, on
Spry1-transfected cells on days 1 (a), 2 (b) and 3 (c) post transfection as compared to the negative controls. MTT assay cell viability results are
shown as optical density (OD) units which are linearly correlated with the cell number. Both assays indicated a significant decrease in growth
and proliferation of the Spry1-transfected cells on day 3 post-transfection. Images are representative of three independent experiments. Data are
shown as mean ± SE. Significant values (<0.05) are marked by asterisks.
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sion of Spry1 in the silenced cells was associated with a
significant increase in their growth and proliferation
assessed at 48 h (p-value: 0.0365) and 72 h (p-value:
0.0228) endpoints. MTTassay of the cell viability (Figure 3C)returned similar results as enhanced growth and proliferation
of 1A9 cells in the Spry1 knockdown group 48 and 72 hours
post silencing (p-values of 0.0011 and 0.0024, respectively).
Collectively, enhanced viability of 1A9 cells was resulted
when the expression of Spry1 was knocked down, in vitro.
Figure 2 Spry1-induced inhibition of wound healing, migration and invasion in SKOV-3 cells. A. Scratch assay imaged at 0, 20 and
24 hours after scratch (left). Data analysis showed a significant decrease in the percent closure by the Spry1 transfection group as compared
to the negative controls (+vector and –vector) 20 and 24 hours after scratch (right). B. Migration assay using 24-well Transwell system (left),
showing a significantly lower number of the migrated cells in the transfection group 6 and 12 hours after plating (right). C. Invasion assay using
matrigel-coated Transwell plates imaged 6 and 12 hours after plating (left), demonstrating a significantly lower number of the invaded cells in the
transfection group assayed at the two endpoints (right). Images are representative of three independent experiments. Data are shown as mean ±
SE. Significant values (<0.05) are marked by asterisks.
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Figure 3 Effect of the Spry1 knockdown on viability, migration and invasion of 1A9 human ovarian cancer cells. A. Western blot analysis
of the Spry1 expression in 1A9 cells after Spry1 silencing with specific siRNA at 24 h (24 h-trans), 48 h (48 h-trans) and 72 h (72 h-trans) as
compared to the control. B. Trypan blue assay and; C. MTT assay on the Spry1-silenced cells and their control counterparts 24 (a), 48 (b), and
72 hours (c) post transfection. MTT assay cell viability results are shown as optical density (OD) units which are linearly correlated with the cell
number. Results show a significant increase in the growth and proliferation of the silenced cells at 48 h and 72 h endpoints. D. Scratch assay
photographed at 0, 24 and 40 hours after scratch (left) shows that the percent closure developed by the Spry1-silenced cells 40 hours after
scratch is significantly higher than that observed in the control group (right). E. Migration assay imaged 14 and 20 hours after plating (left),
showing a significantly higher number of the Spry1-silenced cells migrated at the two endpoints as compared to control (right). F. Invasion assay
imaged at 14 and 20 hours after plating (left), indicating a significantly higher number of the Spry1-silenced cells invaded at the endpoints as
compared to their control counterparts (right). Images are representative of three independent experiments. Data are shown as mean ± SE.
Significant values (<0.05) are marked by asterisks.
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migration and invasion
To investigate the correlation between the expression of
Spry1 and other determinants of a malignant phenotype,
we next tested both Spry1-silenced and control 1A9 cells
for their capability to migrate and invade in vitro. Our
scratch assay (Figure 3D) indicated that Spry1 knock-
down led to a significantly increased percent closure at
the 40 h endpoint (p-value: 0.0259). In the migration
assay, the Spry1-silenced group showed a significantly
higher number of migrated cells 14 (p-value: 0.0125) and
20 hours (p-value: 0.0090) after plating (Figure 3E). The
invasion assay (Figure 3F) indicated that 1A9 cell inva-
sion through the matrigel-coated membrane at hours 14
and 20 was significantly higher in the Spry1-silenced
group (p-values of 0.0298 and 0.0373, respectively).
Taken together, the knocked-down expression of Spry1
resulted in enhanced motility and invasion of 1A9 cells,
in vitro.
Induced expression of Spry1 triggers apoptotic events in
SKOV-3 cells and inhibits activation of ERK and AKT
To investigate the implication of apoptotic processes in
the Spry1-induced growth inhibition found in this study,
the expression of a number of apoptosis-associated pro-
teins in the Spry1-transfected SKOV-3 cells was then ex-
amined. As detected by Western blot 48 hours post
transfection, overexpression of the pro-apoptotic Bax
along with decreased expression of the antiapoptotic
proteins Bcl-2 and Bcl-xl were observed. Attenuation of
procaspases 3, 7, 8 and 9 as well as cleavage of PARP, an
indicator of the caspase 3 activity, was also evident
(Figure 4-left). Given the pivotal role of MAPK/ERK and
AKT pathways in cell proliferation and survival, we next
evaluated the activation status of these pathways after
Spry1 transfection. Our results showed that induced ex-
pression of Spry1 markedly reduced activated forms of
ERK and AKT. Moreover, the expression of phosphatase
and tensin homolog (PTEN), a major negative regulator
of AKT signaling, was found to be increased. This was
accompanied by a concomitant decrease in phospho-
PTEN known as the inactive form of cytoplasmic PTEN(Figure 4-right). No significant change in the expression
pattern of the above proteins was found in the Spry1-
silenced 1A9 cells.
Discussion
Our previous study revealed that human ovarian cancer
cell lines, including SKOV-3 and 1A9, differentially ex-
press Spry1. We observed that while the expression of
Spry1 was moderately positive in 1A9 cells, it was barely
detectable in SKOV-3 cells [8]. Meanwhile, it has been
shown that SKOV-3 and 1A9, respectively, exhibit high
and low potentials for migration [10] and invasion
[11-14]. On this basis, we postulated that the cellular
content of the Spry1 protein, a known downstream regu-
lator of RTK, could be a determinant of the ovarian can-
cer cell behavior. To test our hypothesis, we intended to
examine how alteration of the Spry1 expression in
SKOV-3 and 1A9 could impact their malignant pheno-
type assayable by functional tests. To the best of our
knowledge, this is the first attempt towards exploring
the role of Spry1 in the human epithelial ovarian cancer.
Data from the present study demonstrate that while in-
duced expression of Spry1 in the human ovarian cancer
cell line with minimal Spry1 content (SKOV-3) attenu-
ates cell proliferation and diminishes survival, knock-
down of the protein expression in the Spry1-expressing
cell line (1A9) enhances cell viability. Our findings are in
line with the results from earlier studies on a number of
normal cells. Gross et al. [15] showed that Spry1 inhibits
growth and differentiation of NIH3T3 fibroblasts. Spry1
negative regulation of the endothelial cell proliferation
has been indicated in HUVEC cells by Impagnatiello
et al. [16] and Lee et al. [17]. Using CPAE and ABAE
endothelial cells, Huebert et al. [18] and Sabatel et al.
[19] have consistently reported Spry1-induced inhibition
of the endothelial cell proliferation. Xiang et al. [20]
showed that genistein, a phytoestrogen with potential
cardioprotective effects, modulates proliferation of qui-
escent endothelial cells against that of vascular smooth
muscle cell (VSMC) through regulating the Spry1 ex-
pression. Moreover, Spry1 capability to inhibit growth
and proliferation of cancer cells has been explored by
Figure 4 Western blot analysis of the expression of a number of proteins impacting proliferation and survival of ovarian cancer cells
48 hours after alteration of the Spry1 expression. Results indicate activation of apoptotic processes detected as overexpression of the
pro-apoptotic Bax, decreased expression of the antiapoptotic proteins Bcl-2 and Bcl-xl, attenuation of procaspases 3, 7, 8 and 9 and cleavage of
PARP in the Spry1-transfected SKOV-3 cells (left). Moreover, reduced expression of the activated forms of ERK and AKT along with increased
expression of PTEN with concomitant decrease of phospho-PTEN (right) implicates repression of ERK as well as of AKT, with involvement of PTEN
for the latter, in Spry1-induced inhibition of cell proliferation and survival. No significant change in the expression pattern of these proteins was
found in the Spry1-silenced 1A9 cells.
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overexpression of Spry1 in the prostate cancer cell lines
LNCaP and PC3 had an inhibitory effect on colony for-
mation, cell proliferation and viability. In a study by
Macia et al. [6], the expression of Spry1 reportedly re-
strained the proliferation of the human medullary thyroid
carcinoma cell line TT in vitro and significantly inhibited
tumor growth in the murine xenografts. Jin et al. [5] dem-
onstrated that Pokemon- or miR-21-induced suppression
of Spry1 stimulated growth and proliferation of the QGY-
7703 hepatocellular carcinoma cells while its upregulation
inhibited clonogenic growth and proliferation in vitro.
Sabatel et al. [19] found that the positive Spry1 regulation
induced by 16 K prolactin can delay tumor growth in a
chimeric mouse model of human colon carcinoma.Another aspect of the Spry1 function in our study was
exhibited when induced expression of Spry1 in SKOV-3
cells attenuated cell motility and, conversely, Spry1
knockdown in 1A9 cells promoted migration and inva-
sion. Our lab has already reported that Spry1 is a partner
protein of the urokinase-type plasminogen activator re-
ceptor (uPAR) [21] which is able to inhibit uPAR-
stimulated migration and invasion in the Saos-2 osteo-
sarcoma, MDA-MB-231 breast cancer and HCT116
colorectal cancer cell lines [22]. Overexpression of Spry1
also inhibited migration of HEK293 human embryonic
kidney cells stably transfected with uPAR (HEK293/uPAR).
Our results are in agreement with an earlier study on
ABAE endothelial cells where partial silencing of Spry1 not
only protected ABAE endothelial cells from apoptosis and
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tion in vitro [19].
Exploring mechanisms underlying anti-proliferative
and anti-survival effects of the Spry1 transfection in
ovarian cancer cells, we found that induced expression
of Spry1 activates proapoptotic processes, with implica-
tion of Bcl-2 protein family and caspase pathways. Our
results also indicate that Spry1 expression inhibits acti-
vation of ERK and AKT in SKOV-3 cells. The role of the
Sprouty protein family in regulating ERK and AKT
stimulation of cell proliferation and survival is well doc-
umented [2]. This regulatory function has been studied
in a number of cancer cells, including leiomyosarcoma
[23], cervical [24], liver [25,26] and breast [27] cancer
cells. Moreover, our results implicate PTEN in the Spry1-
induced inhibition of AKT where increased amount and
activity of PTEN accompanied attenuation of AKT
phosphorylation. It has been shown that Sprouty medi-
ates its anti-proliferative effects, at least in part, by in-
creasing the amount and activity of PTEN that in turn
attenuates AKT signaling [24]. Polytarchou et al. [28]
provided evidence that a hypoxia-activated, Akt-
dependent pathway is present in ovarian cancer where
the microRNA miR-21 is induced by Akt and subse-
quently targets and downregulates Spry1, PTEN and
programmed cell death 4 (PDCD4), resulting in en-
hanced cell survival.
Taken together, our results highlight the role of Spry1
in ovarian cancer cell biology. Since such cellular pro-
cesses as proliferation, migration, invasion, and survival
are central to the development, progression, and dissem-
ination of malignant conditions, in-depth understanding
of pertinent regulatory mechanisms and their functional
significance could lead to the development of novel ap-
proaches for enhanced management of cancer. We are
currently conducting a retrospective study to investigate
clinicopathological relevance of the Sprouty expression
profile in patients with ovarian cancer.Conclusions
In summary, we report for the first time that the
Spry1expression inversely correlates with growth, prolif-
eration, invasion and migration of ovarian cancer cells.
Our results suggest that Spry1 may function as a nega-
tive regulator of vitality and survival and an inhibitor of
motility and invasion in human ovarian cancer cell biol-
ogy. In other words, the malignant phenotype of the
ovarian cancer cell lines might be reflected in part by
their ability to differentially express Spry1. Further inves-
tigation is underway to elucidate the role of Spry1 and
other members of the Sprouty family in ovarian cancer
and to evaluate practical value of this protein family in
novel diagnostic, prognostic and therapeutic strategies.Abbreviations
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